Page URL:

Prenatal blood test detects cancer in mothers-to-be

9 March 2015
Appeared in BioNews 793

US company Sequenom has revealed that its prenatal blood test - MaterniT21 PLUS - has detected potential cancer in at least 40 expectant mothers since its launch three years ago.

The non-invasive prenatal test looks at DNA circulating in the mother's bloodstream to identify certain chromosomal abnormalities in the developing fetus. But because the test cannot distinguish between maternal and fetal DNA, it has inadvertently picked up genetic abnormalities in several women, leading to 26 confirmed cancer diagnoses.

At the Future of Genomic Medicine conference in La Jolla, California last week, anaesthesiologist Dr Eunice Lee, 40, told the audience how she had chosen to take the test because of her age. However, she was surprised when, instead of informing her about her baby's genetics, her doctor advised her to undergo a whole-body MRI to look for malignancy.

'The director of the laboratory called my obstetrician and told her I needed to be worked up for cancer, which was just alarming, to her and also to myself, because I had no idea I had cancer,' said Dr Lee.

The subsequent tests revealed a seven centimetre tumour in Dr Lee's colon, which she immediately underwent surgery for. In November, she gave birth to a healthy baby boy.

'I just felt like I was the luckiest person in the world,' Lee said. 'In my case, the test probably saved my life.'

The findings lend weight to a future for so-called 'liquid biopsies' in detecting cancer through routine blood tests - something that several companies, including Sequenom, are looking to explore. However, they also raise new legal and ethical issues around the use of non-invasive prenatal tests, which are not intended for cancer diagnostics and are not regulated by the US Food and Drug Administration (FDA).

BuzzFeed News science editor, Virginia Hughes, explains that the companies that make the tests are caught between the risk of being sanctioned for providing cancer diagnostics from an unlicensed test and the ethical imperative to pass on the information to women so that they can seek a proper diagnosis.

'It’s a funny spot for the lab to be in,' Laura Hercher, a genetic counselor at Sarah Lawrence College in New York state, told Hughes. However, she added that on the other hand, 'it's really hard, ethically, to make the case that you should sit on this information'.

Additionally, the rate of false positives - an important consideration for any diagnostic test - is currently unknown. False positive results can risk a woman undergoing invasive procedures or receiving radiation or chemotherapy unnecessarily.

In the meantime, Sequenom is using what it has learned from these unexpected findings in the development of new tests specifically for cancer. Dirk van dem Boom, the company's chief scientific officer, told BuzzFeed News: 'We’re getting a glimpse of what the technology can do.'

The findings come in the same week that Sequenom announced a net income of US$18.3 million for quarter four of 2014 after reporting a loss for the same period last year. The company also made a profit of 14 cents per share after being forecast a loss of five cents per share.

California Woman Takes Routine Prenatal Test, Finds Out She Has Cancer
KPBS |  5 March 2015
Pregnant Women Are Finding Out They Have Cancer From A Genetic Test Of Their Babies
BuzzFeed |  5 March 2015
Prenatal blood tests detect cancer signal in some women
Reuters |  5 March 2015
Sequenom (press release) |  5 March 2015
Sequenom tops 4Q profit forecasts
CNBC |  4 March 2015
15 August 2016 - by Dr Nicoletta Charolidi 
A study has shown that the chemotherapy drug etoposide can affect the development of fetal ovarian tissue in mice...
7 December 2015 - by Antony Starza-Allen 
The US federal court of appeals has declined to rehear arguments on the patentability of a prenatal blood test, saying that it remains bound by the Supreme Court to determine the claims as non-patentable...
2 November 2015 - by Jessica Richardson 
A man discovered he was not the genetic father of his child, due to a rare form of chimerism that means some of his cells carry a genome belonging to an unborn twin who died in the womb...
14 September 2015 - by Isobel Steer 
A US startup called Pathway Genomics has launched the first commercial 'liquid biopsy' to identify cancerous mutations via a blood test...
1 September 2015 - by Dr Hannah Somers 
Scientists have developed a blood test that can predict several months in advance which breast cancer patients will relapse.
22 September 2014 - by Siobhan Chan 
Women are confident in and value a new non-invasive prenatal test for Down syndrome that is being trialled across a number of maternity clinics in the UK, a study reports...
28 May 2013 - by David O'Rourke 
Medical genetics has changed how we think about diagnosis and treatment in almost every field of medicine. At an evening event hosted by the Royal Society of Medicine (RSM), medical genetics teamed up with obstetrics and gynaecology to explore the impact of genetics on the diagnosis of ovarian and breast cancer....
7 May 2013 - by James Brooks 
I know what they say about yesterday's news and today's fish and chip paper but what I'm about to tell you is six months old and still a little way off as a headline...
14 January 2013 - by Dr Daniel Grimes 
US biotech company Verinata Health has reported sequencing fetal DNA taken from pregnant women's blood to test for genetic abnormalities...
9 July 2012 - by Dr Lux Fatimathas 
US researchers have for the first time sequenced the genome of a fetus using only a blood sample from the mother. It is hoped this new form of non-invasive sampling could allow doctors to screen for a range of genetic diseases prenatally, with minimal risk to the fetus...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.